Immune Mechanisms of Protection Against Mycobacterium tuberculosis Center (IMPAc-TB)

The National Institute of Allergy and Infectious Diseases (NIAID) has released a Broad Agency Announcement (BAA) for the IMPAc-TB program. This initiative focuses on accelerating tuberculosis (TB) vaccine development by investigating protective immune responses. Selected centers will conduct research using human samples, animal models, and computational modeling. Proposals are due by September 1, 2026, and must include an offeror-developed Statement of Work based on the agency's technical objectives. The contract involves extensive collaboration across multiple centers, including bi-monthly coordination calls and annual review meetings. Key requirements include strict adherence to NIH policies for human subjects research, data management, and information technology accessibility. The solicitation document provides the Uniform Contract Format and specific instructions for technical and business proposals. It covers complex research activities including human subjects research, clinical trials, and animal models. The IMPAc-TB program is a research initiative to advance TB vaccine development by studying immune responses through human samples, animal models, and computational analysis.